Locust Walk Insights

 

LOCUST WALK INSIGHTS

Q3 2018 Trends in Biopharma Transactions Report

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q3 2018 Trends in Medtech Transaction Report

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q2 2018 Trends in Medtech Transactions Report

Each quarter, Locust Walk deal team members compile compile key statistics and performance indicators on the latest Medtech transactions. Our Q2 2018 Trends in Medtech Transactions report applies the latest data to analyze current activities in the life...

Q2 2018 Trends in Biopharma Transactions

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q1 2018 Trends in Biopharma Transactions Report

Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia.​ Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...

Q1 2018 Trends in Medtech Transactions Report

Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia.​ Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...

Let’s get digital, digital… 

Often entrepreneurs are describing their new company as a digital health start up, but what exactly is digital health?  Some incorrectly think it is anything medical with a website or connected to an iPad.  In his book, The Fourth Wave, Paul Sonnier describes it as...

Indication Selection for a Platform Company: The Faustian Dilemma

At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients.  Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.  Specifically, many...

Japan & China: So close yet so different

Having lived in Japan for more than 20 years, I have admittedly become perhaps a little too accustomed to the Japanese lifestyle. This is probably why after a few days in the hustle and bustle of Shanghai, I find myself looking forward to returning to the peace and...

Maximizing Your JP Morgan Healthcare Conference

The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors, prospective partners, service providers, etc. and lay the groundwork for much of the...

We’re All Heart: Best in Show at TCT

It is that time of year again when the interventional cardiology and vascular communities reflect on the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting which took place in Denver and finished late last week.  We take pause to remember that TCT is one...

Finding the invisible, how to meet Family Offices

Besides calling the Ghostbusters, how does one catch a ghost?  That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...

Navigating the MedTech Fundraising Environment

For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained. New entrants...